Hot Topics

Breaking

FDA Approves Personalized Cellular Therapy for Advanced Leukemia

Landmark decision for the field of cancer immunotherapy for first therapy based on gene transfer approved by the FDA.

Read more
video

Cancer Immunotherapy Research

20 years of Penn Medicine's "ImmunoRevolution" that has created personalized immunotherapy treatments to reprogram the immune system to recognize and kill cancer cells.

Read more
News

Dr. Bruce Levine Appointed as Deputy Director of Technology Innovation at CCI

New role to coordinate the assessment and integration of new technologies into the continuum of new cellular therapies at the Center for Cellular Immunotherapies (CCI).

Read more
News

Pilot Study Tests CAR T-Cell Immunotherapy in Glioblastomas

Science Translational Medicine reports results of phase 1 safety study of autologous CAR T cells targeted to EGFR variant III in glioblastoma patients.

Read more
News

FDA Approval Recommendation for CAR T-Cell Therapy

FDA advisory committee unanimously approves first personalized cellular therapy developed at Penn for pediatric and young adult leukemia.

Read more
publication

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

A new Penn Medicine preclinical study in Cell, "Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade," suggests that an existing drug known as a JAK in

Read more